Teladoc Health Inc TDOC shares are trading higher in Tuesday's after-hours session after the company reported better-than-expected financial results.
- Q2 Revenue: $652.4 million beat estimates of $649.19 million
- Q2 EPS: loss of 40 cents beat estimates for a loss of 41 cents
Revenues were up 10% on a year-over-year basis. Adjusted gross margin came in at 70.8%, up from 69.2% year-over-year. Adjusted EBITDA was up 54% year-over-year.
Access fees revenue grew 11% to $575.7 million, and other revenue grew 4% to $76.7 million. U.S. revenue grew 8% to $561.8 million, and International revenue grew 28% to $90.6 million.
Cash flow from operations totaled $101.2 million. Free cash flow came in at $64.6 million.
"This performance is a direct result of introducing and expanding new products and services, investing in a robust innovation pipeline, controlling expenses, and vertically integrating care to capitalize on customer demand for unified virtual and in-person healthcare experiences," said Jason Gorevic, CEO of Teladoc.
Outlook: Teladoc sees third-quarter revenue in the range of $650 million to $675 million versus estimates of $663.11 million. The company anticipates a third-quarter loss of 40 to 50 cents per share versus estimates for a loss of 33 cents per share.
Teladoc expects full-year 2023 revenue to be between $2.6 billion and $2.675 billion versus estimates of $2.63 billion. The company sees a full-year earnings loss of $1.25 to $1.60 per share versus estimates for a loss of $1.34 per share.
TDOC Price Action: Teladoc shares were up 9.02% after hours at $24.84 at the time of publication, according to Benzinga Pro.
Photo: courtesy of Teladoc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.